Acacia Communications (ACIA) Was Downgraded by Bank of America to Neutral; Corbus Pharmaceuticals Holdings (CRBP) SI Increased By 3.21%

April 17, 2018 - By Lawrence Diaz

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Logo

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) had an increase of 3.21% in short interest. CRBP’s SI was 8.96M shares in April as released by FINRA. Its up 3.21% from 8.68 million shares previously. With 762,500 avg volume, 12 days are for Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)’s short sellers to cover CRBP’s short positions. The SI to Corbus Pharmaceuticals Holdings Inc’s float is 20.57%. The stock decreased 0.76% or $0.05 during the last trading session, reaching $6.55. About 159,179 shares traded. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has declined 38.80% since April 17, 2017 and is downtrending. It has underperformed by 50.35% the S&P500.

In a analysts note shared with investors and clients on 17 April, Bank of America has decreased Acacia Communications (ACIA) stock to Neutral. ACIA’s old rating was Buy.

Analysts await Acacia Communications, Inc. (NASDAQ:ACIA) to report earnings on May, 8. They expect $-0.07 earnings per share, down 108.14% or $0.93 from last year’s $0.86 per share. After $0.12 actual earnings per share reported by Acacia Communications, Inc. for the previous quarter, Wall Street now forecasts -158.33% negative EPS growth.

The stock increased 2.42% or $0.62 during the last trading session, reaching $26.25. About 3.07 million shares traded or 318.22% up from the average. Acacia Communications, Inc. (ACIA) has declined 30.95% since April 17, 2017 and is downtrending. It has underperformed by 42.50% the S&P500.

Acacia Communications, Inc. develops, makes, and sells high-speed coherent optical interconnect products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. The company has market cap of $1.05 billion. The Company’s products include a series of low-power coherent digital signal processors application-specific integrated circuits and silicon photonic integrated circuits integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per second for use in long-haul, metro, and inter-data center markets. It has a 28.53 P/E ratio. The firm sells its products through a direct sales force to network equipment manufacturers.

Among 16 analysts covering Acacia Communi… (ACIA), 9 have Buy rating, 1 Sell and 6 Hold. Therefore 56% are positive. Acacia Communi… has $125.0 highest and $2600 lowest target. $46.36’s average target is 76.61% above currents $26.25 stock price. Acacia Communi… had 46 analyst reports since June 7, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, August 22 by Needham. The stock of Acacia Communications, Inc. (NASDAQ:ACIA) earned “Buy” rating by Needham on Tuesday, June 7. UBS initiated it with “Buy” rating and $50.0 target in Wednesday, January 31 report. The company was maintained on Friday, February 23 by UBS. As per Monday, July 17, the company rating was maintained by Cowen & Co. The firm has “Buy” rating by Needham given on Tuesday, October 11. As per Tuesday, June 7, the company rating was initiated by Goldman Sachs. The stock of Acacia Communications, Inc. (NASDAQ:ACIA) has “Overweight” rating given on Thursday, February 2 by Morgan Stanley. The rating was initiated by Cowen & Co on Tuesday, June 7 with “Outperform”. The stock has “Buy” rating by Northland Capital on Friday, September 15.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. The company has market cap of $374.23 million. The Company’s lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. It currently has negative earnings.

Among 5 analysts covering Corbus Pharma (NASDAQ:CRBP), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corbus Pharma had 21 analyst reports since September 8, 2015 according to SRatingsIntel. As per Tuesday, August 8, the company rating was maintained by Noble Financial. As per Thursday, December 14, the company rating was maintained by Cantor Fitzgerald. The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) earned “Buy” rating by Noble Financial on Friday, December 15. The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) earned “Buy” rating by Cantor Fitzgerald on Wednesday, August 9. As per Tuesday, June 13, the company rating was maintained by Cantor Fitzgerald. The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has “Buy” rating given on Monday, March 7 by Aegis Capital. On Thursday, October 19 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Cantor Fitzgerald maintained it with “Buy” rating and $32.0 target in Monday, March 12 report. Raymond James initiated the shares of CRBP in report on Thursday, January 18 with “Buy” rating. As per Friday, November 10, the company rating was maintained by Noble Financial.

Acacia Communications, Inc. (NASDAQ:ACIA) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>